F070 Updates on Melanoma Diagnosis and Therapy
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The standard of care for the diagnosis and treatment of melanoma is changing at an unprecedented rate. Advances in the molecular understanding of human melanoma and the host immune response to this aggressive skin cancer are progressing rapidly and quickly translating into improvements in patient outcomes. Here we review the latest advances in the detection and treatment of melanoma. Participants will leave with a clear understanding of current standards of practice. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Describe the latest innovations for prevention, early detection, and diagnosis of melanoma
Identify current tools available to assist with melanoma prognosis
Distinguish appropriate use of current and novel therapies in melanoma
SCHEDULE
11:30 PM
Strategies to Improve Melanoma Detection: Primary Care Partnerships, eConsult, ECHO, Dermoscopy, Melanoma Mapping and More...
Elizabeth V. Seiverling, MD
11:45 PM
Projected Burden of Melanoma Clinical Surveillance
Charles N. Ellis, MD, FAAD
11:55 PM
Melanoma Prevention: Innovations in Sunscreens/Photoprotection
Tasneem Mohammad, MD, FAAD
12:05 AM
Before the Blade: Current Application and Future Direction for Non-Invasive Imaging for Pigmented Lesions
Michael Christopher Kwa, MD, FAAD
12:20 AM
Q&A
Charles N. Ellis, MD, FAAD, Michael Christopher Kwa, MD, FAAD, Tasneem Mohammad, MD, FAAD, Elizabeth V. Seiverling, MD
12:30 AM
Melanoma Normograms: Change Coming to When to do a Sentinel Node?
Wesley Yu, MD, FAAD
12:40 AM
GEP: Where it Fits into Workup
Jennifer A. Stein, MD, PhD, FAAD
12:50 AM
Medicine for Melanoma: Advances in the Timing of Immunotherapy (eg, neoadjuvant)
Susan M. Swetter, MD, FAAD
1:05 AM
Managing Dermatologic Side Effects from Immunotherapy
Anna Axelson, MD, FAAD
1:15 AM
Q&A
Anna Axelson, MD, FAAD, Jennifer A. Stein, MD, PhD, FAAD, Susan M. Swetter, MD, FAAD, Wesley Yu, MD, FAAD
SPEAKERS
Rhoda Myra Alani, MD, FAAD
Anna Axelson, MD, FAAD
Charles N. Ellis, MD, FAAD
Michael Christopher Kwa, MD, FAAD
Tasneem Mohammad, MD, FAAD
Elizabeth V. Seiverling, MD
Jennifer A. Stein, MD, PhD, FAAD
Susan M. Swetter, MD, FAAD
Wesley Yu, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Rhoda Myra Alani, MD, FAAD
Acylin Therapeutics, Inc – Founder(No Compensation Received);
Anna Axelson, MD, FAAD
No financial relationships exist with ineligible companies.
Charles N. Ellis, MD, FAAD
BirchBioMed – Board of Directors(Stock Options), Consultant(Fees); Formation Bio – Independent Contractor(Stock Options); Lipidio Pharmaceuticals – Independent Contractor(Fees), Independent Contractor(Stock); LS-Psoriasis Global Assessment – Founder(Patent royalties or other compensation for Intellectual Property Rights); Medsphere Systems Corporation – Stockholder(No Compensation Received); Senju Pharmaceutical Co. – Consultant(Fees); Thirona – Independent Contractor(Fees), Independent Contractor(Stock Options); VisualDx – Stockholder(No Compensation Received);
Michael Christopher Kwa, MD, FAAD
No financial relationships exist with ineligible companies.
Tasneem Mohammad, MD, FAAD
atheneum – Consultant(Honoraria), Consultant (1099 relationship)(Fees); Avita – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Beiersdorf – Consultant (1099 relationship)(Fees); Beiersdorf, Inc. – Speaker(Honoraria); Clinuvel – Investigator(Grants/Research Funding); Ferndale Laboratories, Inc. – Advisory Board(Honoraria); Guidepoint Global, LLC – Consultant(Honoraria); Immune Tolerance Network – Investigator(Grants/Research Funding); Incyte – Advisory Board(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); KeyQuest Health – Consultant (1099 relationship)(Fees); Medscape – Speaker/Faculty Education(Honoraria); Mitsubishi Tanabe Pharma Corporation – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); polaris health – Speaker/Faculty Education(Honoraria); Research America – Consultant(Honoraria); TheraVida – Consultant(Fees); Third Bridge – Consultant (1099 relationship)(Honoraria); Unigen – Investigator(Grants/Research Funding);
Elizabeth V. Seiverling, MD
No financial relationships exist with ineligible companies.
Jennifer A. Stein, MD, PhD, FAAD
UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);
Susan M. Swetter, MD, FAAD
No financial relationships exist with ineligible companies.
Wesley Yu, MD, FAAD
Castle Biosciences – Advisory Board(Honoraria); SkylineDx B.V. – Investigator(Grants/Research Funding);